Heidelberg Pharma AG HPHA-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 11:47 AM CEST
5.62quote price arrow down-0.08 (-1.40%)
Volume
1,750
52 week range
3.40 - 6.90
Loading...
  • Open5.54
  • Day High5.62
  • Day Low5.54
  • Prev Close5.64
  • 52 Week High6.90
  • 52 Week High Date08/20/21
  • 52 Week Low3.40
  • 52 Week Low Date01/25/22

Key Stats

  • Market Cap195.59M
  • Shares Out34.18M
  • 10 Day Average Volume1,964.5
  • Dividend-
  • Dividend Yield-
  • Beta-1.64
  • YTD % Change19.32

KEY STATS

  • Open5.54
  • Day High5.62
  • Day Low5.54
  • Prev Close5.64
  • 52 Week High6.90
  • 52 Week High Date08/20/21
  • 52 Week Low3.40
  • 52 Week Low Date01/25/22
  • Market Cap195.59M
  • Shares Out34.18M
  • 10 Day Average Volume1,964.5
  • Dividend-
  • Dividend Yield-
  • Beta-1.64
  • YTD % Change19.32

RATIOS/PROFITABILITY

  • EPS (TTM)-0.63
  • P/E (TTM)-8.92
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Heidelberg Pharma AG

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based company engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC...
Jan Schmidt-Brand
Chief Executive Officer, Chief Financial Officer, Member of the Executive Management Board
Address
Schriesheimer Strasse 101
Ladenburg
68526
Germany